Drugs / Tongjiang granule
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05312463 | Mar 2022 → Oct 2023 | gastroesophageal reflux disease, voice disorders | Xiyuan Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tongjiang granule | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05312463 ↗ |
| Route | Oral | “oral administration of Tongjiang granule with warm water after meal” NCT05312463 ↗ |